OmniSeq INSIGHT | Labcorp Oncology

Profiling Empowers
You to Make Better Decisions

From a single tumor biopsy, analyzed by advanced next generation sequencing (NGS) technology,
OmniSeq INSIGHT identifies treatment options in one comprehensive, easy-to-read report.

Genomic Profiling

523 Gene NGS Panel
Microsatellite instability (MSI) and tumor mutational burden (TMB)
DNA and RNA sequencing
Single nucleotide variants (SNVs) – insertions/deletions (indels), copy number alterations (CNAs) and fusions
Interrogation of full coding regions
HLA genotyping

Immune Profiling

PD-L1 by immunohistochemistry (IHC)
64 RNA expression/immune profiling genes by immune cycle step:
- T-cell priming/trafficking
- T-cell recognition
- T-cell infiltration
- Killing cancer cells
- Cancer testis antigens

Brochure Gene List

Why Choose OmniSeq INSIGHT?

1

Single Tumor Biopsy

A single tissue sample provides complete insight into the tumor and its microenvironment.

2

Pan-Cancer Testing

The report provides comprehensive genomic and immune profiling for all solid tumors.

3

Treatment Options

A summary of FDA-approved therapies, immunotherapies and eligible clinical trials tailored to your patient’s solid tumor.

Identify Approved Drug Candidates

Comprehensive Genomics
- Detects all four main classes of genomic alterations
- Fusions / splice variants using RNA-Seq hybrid capture
- Coverage of clinical practice guideline-recommended biomarkers across solid tumor types

Immunotherapy Eligibility

Comprehensive Immune Profiling
- MSI & TMB profiling
- PD-L1 by IHC
- Immune biomarker drug targets

Eligible Clinical Trials

List of patient-eligible clinical trials within 200 miles of patient’s physical address¹
- Testing for biomarkers with clinical trial associations

Patient Reports: Concise, Comprehensive & Actionable

Comprehensive Quick-Read Results

Gain actionable insights at a glance with:

Clinically significant results
Pertinent negative genomic variants
A therapy considerations summary
Flagged potential cancer-associated hereditary variants

THERAPY CONSIDERATIONS

Start to formulate a plan with:

Full-label indications
Treatment setting and approval status
Guideline evidence
Emerging clinical benefits

MARKER DETAILS

See the bigger picture with:

Full biomarker details
Gene, variant and prevalence information

Clinical Trial Options

Expand your patient’s options with:

Number of trial matches per marker
Clinical significance for matched trials
Highly-expressed/positive immune genes with trials

Sample requirements (include pathology report)
Formalin fixed paraffin embedded (FFPE) tissue Resection specimens Needle core biopsy specimens Cell blocks from fine needle aspirates (FNAs) Do not submit decalcified specimens, cytology smears or samples from hematologic malignancies
FFPE block (preferred) or 20 unbaked, positively charged, unstained slides cut a 5 µm plus one H&E
Turnaround time: 12-14 Days

Sample requirements (include pathology report)

Formalin fixed paraffin embedded (FFPE) tissue